Information Provided By:
Fly News Breaks for May 23, 2017
PRXL
May 23, 2017 | 06:01 EDT
Goldman analyst Robert Jones upgraded Parexel to Neutral and raised its price target to $77 from $63 to reflect reduced consensus expectations and industry consolidation. The analyst said two large-scale Clinical transactions announced over the past month reinforce his view of consolidation in the CRO space and reduced downside risk for Parexel.
News For PRXL From the Last 2 Days
There are no results for your query PRXL